Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfiz­er and Roivant are team­ing up to launch a new ‘Vant’ aimed at bring­ing a mid-stage an­ti-in­flam­ma­to­ry drug to mar­ket, the pair an­nounced Thurs­day.

There’s no name for the start­up yet, nor are there any em­ploy­ees. Thus far, the new com­pa­ny and Roivant can be con­sid­ered “one and the same,” Roivant CEO Matt Gline tells End­points News. But Pfiz­er is so en­thu­si­as­tic about the tar­get that it elect­ed to keep 25% of eq­ui­ty in the drug rather than take up­front cash from Roivant, Gline said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER